Clinical

Dataset Information

0

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers


ABSTRACT: The purpose of this study is to determine the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) (or the highest protocol-defined dose level in the absence of establishing an MTD) of ibrutinib in combination with pembrolizumab in participants with advanced, refractory colorectal cancers.

DISEASE(S): Colorectal Carcinoma,Colon Disease,Colon Cancer,Colorectal Cancer,Colorectal Neoplasms,Colonic Diseases

PROVIDER: 2258148 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2294936 | ecrin-mdr-crc
2015-11-11 | GSE66999 | GEO
2022-11-16 | GSE212521 | GEO
| 2097031 | ecrin-mdr-crc
2011-11-21 | E-GEOD-32035 | biostudies-arrayexpress
| 2066127 | ecrin-mdr-crc
2009-04-01 | GSE12062 | GEO
2011-11-21 | GSE32035 | GEO
| 2144055 | ecrin-mdr-crc
| 2466336 | ecrin-mdr-crc